文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

An integrative analysis reveals cancer risk associated with artificial sweeteners.

作者信息

Xie Jumin, Zhu Ying, Yang Zixuan, Yu Zhang, Yang Mingzhi, Wang Qingzhi

机构信息

Hubei Key Laboratory of Renal Disease Occurrence and Intervention, Medical School, Hubei Polytechnic University, Guilin North Road No 16, Huangshi, 435003, Hubei, People's Republic of China.

Medical College of YiChun University, Xuefu Road No 576, Yichun, 336000, Jiangxi, People's Republic of China.

出版信息

J Transl Med. 2025 Jan 8;23(1):32. doi: 10.1186/s12967-024-06047-0.


DOI:10.1186/s12967-024-06047-0
PMID:39780215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11708064/
Abstract

BACKGROUND: Artificial sweeteners (AS) have been widely utilized in the food, beverage, and pharmaceutical industries for decades. While numerous publications have suggested a potential link between AS and diseases, particularly cancer, controversy still surrounds this issue. This study aims to investigate the association between AS consumption and cancer risk. METHODS: Targets associated with commonly used AS were screened and validated using databases such as CTD, STITCH, Super-PRED, Swiss Target Prediction, SEA, PharmMapper, and GalaxySagittarius. Cancer-related targets were sourced from GeneCards, OMIM, and TTD databases. AS-cancer targets were identified through the intersection of these datasets. A network visualization ('AS-targets-cancer') was constructed using Cytoscape 3.9.0. Protein-protein interaction analysis was conducted using the STRING database to identify significant AS-cancer targets. GO and KEGG enrichment analyses were performed using the DAVID database. Core targets were identified from significant targets and genes involved in the 'Pathways in cancer' (map05200). Molecular docking and dynamics simulations were employed to verify interactions between AS and target proteins. Pan-cancer and univariate Cox regression analyses of core targets across 33 cancer types were conducted using GEPIA 2 and SangerBox, respectively. Gene chip datasets (GSE53757 for KIRC, GSE21354 for LGG, GSE42568 for BRCA, and GSE46602 for PRAD) were retrieved from the GEO database, while transcriptome and overall survival data were obtained from TCGA. Data normalization and identification of differentially expressed genes (DEGs) were performed on these datasets using R (version 4.3.2). Gene Set Enrichment Analysis (GSEA) was employed to identify critical pathways in the gene expression profiles between normal and cancer groups. A cancer risk prognostic model was constructed for key targets to further elucidate their significance in cancer initiation and progression. Finally, the HPA database was utilized to investigate variations in the expression of key AS-cancer target proteins across KIRC, LGG, BRCA, PRAD, and normal tissues. RESULTS: Seven commonly used AS (Aspartame, Acesulfame, Sucralose, NHDC, Cyclamate, Neotame, and Saccharin) were selected for study. A total of 368 AS-cancer intersection targets were identified, with 48 notable AS-cancer targets, including TP53, EGFR, SRC, PIK3R1, and EP300, retrieved. GO biological process analysis indicated that these targets are involved in the regulation of apoptosis, gene expression, and cell proliferation. Thirty-five core targets were identified from the intersection of the 48 significant AS-cancer targets and genes in the 'Pathways in cancer' (map05200). KEGG enrichment analysis of these core targets revealed associations with several cancer types and the PI3K-Akt signaling pathway. Molecular docking and dynamics simulations confirmed interactions between AS and these core targets. HSP90AA1 was found to be highly expressed across the 33 cancer types, while EGF showed the opposite trend. Univariate Cox regression analysis demonstrated strong associations of core targets with KIRC, LGG, BRCA, and PRAD. DEGs of AS-cancer core targets across these four cancers were analyzed. GSEA revealed upregulated and downregulated pathways enriched in KIRC, LGG, BRCA, and PRAD. Cancer risk prognostic models were constructed to elucidate the significant roles of key targets in cancer initiation and progression. Finally, the HPA database confirmed the crucial function of these targets in KIRC, LGG, BRCA, and PRAD. CONCLUSION: This study integrated data mining, machine learning, network toxicology, molecular docking, molecular dynamics simulations, and clinical sample analysis to demonstrate that AS increases the risk of kidney cancer, low-grade glioma, breast cancer, and prostate cancer through multiple targets and signaling pathways. This paper provides a valuable reference for the safety assessment and cancer risk evaluation of food additives. It urges food safety regulatory agencies to strengthen oversight and encourages the public to reduce consumption of foods and beverages containing artificial sweeteners and other additives.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/a1f7568e8df6/12967_2024_6047_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/2e34aa1774a6/12967_2024_6047_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/308da57ea2c3/12967_2024_6047_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/d66ccb4f3923/12967_2024_6047_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/14ecd0af3973/12967_2024_6047_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/734fec0ad993/12967_2024_6047_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/1898b293f597/12967_2024_6047_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/a5300d9a7194/12967_2024_6047_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/4f2d4aa76b69/12967_2024_6047_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/7471cc526ac9/12967_2024_6047_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/3bb60731c349/12967_2024_6047_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/d6f561bb47c5/12967_2024_6047_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/a1f7568e8df6/12967_2024_6047_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/2e34aa1774a6/12967_2024_6047_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/308da57ea2c3/12967_2024_6047_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/d66ccb4f3923/12967_2024_6047_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/14ecd0af3973/12967_2024_6047_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/734fec0ad993/12967_2024_6047_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/1898b293f597/12967_2024_6047_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/a5300d9a7194/12967_2024_6047_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/4f2d4aa76b69/12967_2024_6047_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/7471cc526ac9/12967_2024_6047_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/3bb60731c349/12967_2024_6047_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/d6f561bb47c5/12967_2024_6047_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39ff/11708064/a1f7568e8df6/12967_2024_6047_Fig12_HTML.jpg

相似文献

[1]
An integrative analysis reveals cancer risk associated with artificial sweeteners.

J Transl Med. 2025-1-8

[2]
Research on the Regulatory Mechanism of Ginseng on the Tumor Microenvironment of Colorectal Cancer based on Network Pharmacology and Bioinformatics Validation.

Curr Comput Aided Drug Des. 2024

[3]
Network pharmacology and transcriptomics reveal the mechanisms of FFBZL in the treatment of oral squamous cell carcinoma.

Front Pharmacol. 2024-9-11

[4]
Exploring the Targets and Molecular Mechanisms of Curcumin for the Treatment of Bladder Cancer Based on Network Pharmacology, Molecular Docking and Molecular Dynamics.

Mol Biotechnol. 2025-5

[5]
Understanding apoptotic induction by Sargentodoxa cuneata-Patrinia villosa herb pair via PI3K/AKT/mTOR signalling in colorectal cancer cells using network pharmacology and cellular studies.

J Ethnopharmacol. 2024-1-30

[6]
Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking.

Heliyon. 2024-6-19

[7]
Investigating the Molecular Mechanisms of Resveratrol in Treating Cardiometabolic Multimorbidity: A Network Pharmacology and Bioinformatics Approach with Molecular Docking Validation.

Nutrients. 2024-7-31

[8]
Analysis of action of 1,4-naphthoquinone scaffold-derived compounds against acute myeloid leukemia based on network pharmacology, molecular docking and molecular dynamics simulation.

Sci Rep. 2024-9-9

[9]
To Reveal the Potential Mechanism of Quercetin against NSCLC Based on Network Pharmacology and Experimental Validation.

Comb Chem High Throughput Screen. 2024-10-21

[10]
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.

BMC Cancer. 2021-6-23

引用本文的文献

[1]
Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration.

Front Pharmacol. 2025-8-13

[2]
Research on the association between beverages consumption and cancer.

Front Med (Lausanne). 2025-8-1

[3]
Multi-omics analysis of the anti-cancer effects of curcumol in endometrial carcinoma.

Front Pharmacol. 2025-7-3

[4]
Metagenomics and transcriptomics analysis of aspartame's impact on gut microbiota and glioblastoma progression in a mouse model.

Sci Rep. 2025-7-2

本文引用的文献

[1]
Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma.

Cancer Res. 2025-3-3

[2]
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.

Cancer Res. 2025-3-3

[3]
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer.

Cancer Res. 2025-2-1

[4]
ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer.

NPJ Precis Oncol. 2024-11-4

[5]
Associations of saccharin intake with all-cause, cardiovascular and cancer mortality risk in USA adults.

Br J Nutr. 2024-11-4

[6]
Tumor-secreted LCN2 impairs gastric cancer progression via autocrine inhibition of the 24p3R/JNK/c-Jun/SPARC axis.

Cell Death Dis. 2024-10-18

[7]
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

Br J Cancer. 2024-11

[8]
Repeated FRAP of the actin-binding protein CapG in the cell nucleus-a functional assay for EGF signaling in the single live breast cancer cell.

Sci Rep. 2024-10-5

[9]
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants.

JAMA Oncol. 2024-11-1

[10]
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications.

Semin Cancer Biol. 2024-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索